High Lifelong Testosterone Linked to Coronary Artery Disease in Men, New Cambridge Study

Originally surfaced May 11, 2026, drawing on a Cambridge analysis first published earlier in 2026.

A University of Cambridge genetic study analyzing data from more than 1.4 million people found that men carrying gene variants associated with higher lifelong circulating testosterone had a 17 percent greater risk of developing coronary artery disease. The increased risk appeared to be partly mediated by higher blood pressure in those men. This finding was published earlier in 2026 and has been generating discussion in cardiology and endocrinology circles since.

This is a finding about endogenous testosterone, meaning the testosterone a man's own body produces, not about prescribed testosterone therapy. That distinction matters. The same general time window has produced cardiovascular safety data for testosterone replacement therapy that points in a more reassuring direction, particularly the TRAVERSE trial, which found that appropriately prescribed TRT in men with confirmed hypogonadism did not significantly raise major adverse cardiovascular events, while still flagging higher rates of certain adverse events including pulmonary embolism, acute kidney injury, and atrial fibrillation.

What the Cambridge study is actually measuring

The study is a Mendelian randomization analysis. It uses genetic variants that influence testosterone levels as a proxy for lifelong testosterone exposure. That approach is closer to a natural randomized experiment than ordinary observational research, and it strengthens the case for a real biological link rather than a confounded one.

What it does not do is tell you that a single point-in-time testosterone reading is a cardiovascular risk score. It also does not tell you that having high natural testosterone is the same thing as taking testosterone therapy. The two are biologically and clinically different.

How to think about a testosterone reading

For most men, a testosterone test is ordered to evaluate symptoms (low libido, fatigue, mood changes, reduced morning erections, loss of muscle mass) or to investigate fertility. The interpretive framework is symptom-anchored. A number alone does not make the diagnosis.

The Cambridge finding adds a different consideration: high testosterone is not automatically better. There is a real cardiovascular tradeoff that is now better characterized, especially via the blood-pressure pathway. That matters more for men evaluating whether to chase higher testosterone numbers than for men confirming a clinically suspected deficiency.

The lab options

LabTestSuperstore offers the free and total testosterone test for a more complete read than total testosterone alone. The total testosterone test is the basic option. The comprehensive testosterone test packages additional context. The men's hormone panel - basic and men's hormone panel - expanded bundle testosterone with related hormones such as LH, FSH, SHBG, estradiol, and prolactin.

For cardiovascular context alongside testosterone, the lipid panel and ApoB test are higher-resolution. For background, see our low testosterone symptoms page, our heart disease risk page, and our high blood pressure labs page.

This article is editorial commentary and is not medical advice. Decisions about testosterone testing or therapy should be made with a clinician familiar with your personal symptoms, risk factors, and goals.